Zimmer Biomet Holdings, Inc. (ZBH) To Go Ex-Dividend on March 31st

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) announced a quarterly dividend on Monday, February 23rd. Shareholders of record on Tuesday, March 31st will be given a dividend of 0.24 per share by the medical equipment provider on Thursday, April 30th. This represents a c) annualized dividend and a dividend yield of 1.1%. The ex-dividend date is Tuesday, March 31st.

Zimmer Biomet has a payout ratio of 11.5% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect Zimmer Biomet to earn $8.87 per share next year, which means the company should continue to be able to cover its $0.96 annual dividend with an expected future payout ratio of 10.8%.

Zimmer Biomet Stock Down 0.8%

NYSE:ZBH opened at $88.41 on Friday. The company’s 50-day simple moving average is $92.00 and its 200-day simple moving average is $94.07. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.10 and a current ratio of 1.98. Zimmer Biomet has a fifty-two week low of $84.59 and a fifty-two week high of $114.44. The stock has a market capitalization of $17.30 billion, a P/E ratio of 24.98, a P/E/G ratio of 1.81 and a beta of 0.58.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Tuesday, February 10th. The medical equipment provider reported $2.42 EPS for the quarter, topping the consensus estimate of $2.38 by $0.04. The firm had revenue of $2.24 billion during the quarter, compared to analyst estimates of $2.22 billion. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. Zimmer Biomet’s revenue was up 10.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.31 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. On average, equities analysts anticipate that Zimmer Biomet will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.